ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

FDA Approves Abaloparatide to Treat Men with Osteoporosis & a High Risk of Fracture

Michele B. Kaufman, PharmD, BCGP  |  February 15, 2023

In late December, the FDA approved subcutaneous abaloparatide for the treatment of men with osteoporosis at a high risk of fracture. This approval is based on a placebo-controlled study that showed abaloparatide led to significant increases in bone mineral density of the lumbar spine, total hip and femoral neck. Abaloparatide was approved in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:abaloparatideFDAFDA approvalOsteoporosisosteoporosis treatmentsU.S. Food and Drug Administration (FDA)

ACR Convergence 2022 Closing Session Discusses Research Highlights

Thomas R. Collins  |  February 15, 2023

PHILADELPHIA—Expert panelists gathered in the closing session at ACR Convergence 2022 to give their take on what they saw as some of the most notable research findings and other insights to come out of the meeting, touching on a number of topics on the leading edge of the field. COVID-19 Prophylaxis & Vaccinations Alfred Kim,…

Filed under:ACR ConvergenceConditionsResearch RheumRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR Convergence 2022COVID-19Osteoarthritisvaccination

ACR Image Competition 2022 Results, Part 3

Masaki Itagane, MD  |  February 15, 2023

Localized Scleroderma in Anti-NXP2-Antibody Positive Dermatomyositis A 67-year-old woman presented with erythematous, indurated skin on her left flanks. She had been diagnosed with dermatomyositis one year earlier when proximal muscle weakness, dysphagia and skin rash developed (see Figure A). Tests at the time showed the presence of anti-NXP2 and anti-Ro52 antibodies, as well as pathological…

Filed under:ConditionsMyositisSystemic Sclerosis Tagged with:calcinosisdermatomyositisImage Competition

Case Report: World Trade Center Dust Stokes a Foreign Body Reaction

Branden Ireifej, MD, Lea Meir, MD, Emily Gutowski, MD, Hansen Lam, MD, & Wei Wei Chi, MD  |  February 14, 2023

The terrorist attacks on the Twin Towers at the World Trade Center (WTC) that led to their destruction on Sept. 11, 2001, as well as the subsequent year-long cleanup of the site (i.e., Ground Zero) in 2001 and 2002, not only had immediate implications for the lives and health of thousands of individuals at the…

Filed under:ConditionsVasculitis Tagged with:FellowsFellows Forum

Case Report: A Long, Arduous Evaluation Capped by Genetic Testing

Saud Abaalkhail, MD, Muhammad Umair Javaid, DO, & Amarie Negron Rodriguez, MD  |  February 14, 2023

Systemic autoinflammatory diseases (SAIDs) are rare syndromes characterized by alterations in innate immunity that result in a variety of clinical manifestations that are usually associated with recurrent fevers.1 Thanks to advances in genetic sequencing over the past few years, monogenic causes for some of these autoinflammatory diseases, such as Yao syndrome, have been discovered.2 Previously…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:canakinumabcase reportNOD2-associated auto­inflammatory diseaseYao Syndrome

Case Report: Adult-Onset Still’s Disease with Complications

Cristina Romaniello, DO, & Caitlin Kesari, MD  |  February 14, 2023

The following report outlines a case of newly diagnosed adult-onset Still’s disease (AOSD) complicated by macrophage activation syndrome (MAS) in a previously healthy and active 32-year-old man who had emigrated from Africa to the U.S. Case A man with no prior medical history presented with acute-onset polyarthritis, fevers and fatigue that began one month previously….

Filed under:ConditionsOther Rheumatic Conditions Tagged with:adult Still's Diseasecase reportmacrophage activation syndrome

RheumMadness 2023: the All-Star Season

David L. Leverenz, MD, MEd  |  February 13, 2023

RheumMadness is back for its third season, and everyone who is crazy about rheumatology is welcome to play. That includes practicing rheumatologists, fellows, residents, medical students, advanced practice providers, other healthcare professionals and patients. Basically, if you are reading this article, you can play RheumMadness. RheumMadness is an online tournament in which a bracket of…

Filed under:Education & TrainingResearch Rheum Tagged with:FellowsFellows-in-Trainingonline educationRheumatology Research FoundationRheumMadness

Rheumatology Online: The State of the Art on Social Media

Mithu Maheswaranathan, MD  |  February 9, 2023

PHILADELPHIA—A session on social media in rheumatology at ACR Convergence 2022 focused on how to use social media to promote one’s work and collaborate on international research projects, as well as the use of podcasts in educating rheumatologists. Engaging at Conferences Jean Liew, MD, MS, assistant professor of medicine in the Section of Rheumatology at…

Filed under:ACR ConvergenceAmerican College of RheumatologyEducation & TrainingMeeting ReportsTechnology Tagged with:ACR Convergence 2022EducationpodcastSocial MediaTechnology

Healthcare Policy Prospects in the 118th Congress

From the College  |  February 4, 2023

The U.S. government remains divided. Democrats hold the White House and the Senate by one vote, and Republicans lead the House. Amid this division, the ACR is watching possible areas to advance healthcare legislation. Meet the committees and members with the largest jurisdiction over healthcare policy.

Filed under:Legislation & Advocacy Tagged with:ACR advocacyhealthcare lawpolicy issuesU.S. Congress

Reform of Medicare Payment System Needed to Maintain Patient Care, ACR Says

From the College  |  February 2, 2023

In a joint letter, the ACR urges Congress to undergo comprehensive reform of the Medicare payment system and seek long-term payment solutions that will allow clinicians to continue to care for Medicare patients.

Filed under:Legislation & Advocacy Tagged with:ACR advocacyMedicare Physician Fee Schedule (MPFS)physician payment reform

  • « Previous Page
  • 1
  • …
  • 41
  • 42
  • 43
  • 44
  • 45
  • …
  • 328
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences